Indian drugmaker Lupin has signed an agreement to acquire US-based Gavis Pharmaceuticals and Novel Laboratories (Gavis) for around $880m.

The acquired business will expand Lupin’s presence in the US generic market, in addition to expanding its portfolio in dermatology, controlled substance products and other niche generics.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Lupin CEO Vinita Gupta said: "Gavis has a strong track record of delivering highly differentiated products in a short time and is poised for continued strong growth as it delivers on its existing pipeline.

"This is a time of globalisation for the specialty pharmaceutical industry and Gavis is well-positioned to capitalise on this exciting opportunity."

Based in New Jersey, Gavis is involved in formulation development, manufacturing, packaging, sales, marketing, and distribution of pharmaceuticals products.

Currently, the firm has 66 ANDA filings pending approval with the US FDA, as well as pipeline of around 65 niche dosage forms. The company has also filed 25 Para IVs and eight FTFs products.

See Also:

According to Lupin, Gavis’ pending filings are expected to have a market value of around $9bn and the combination will include a portfolio of 101 in-market products, 164 cumulative filings pending approval and a pipeline of products under development for the US.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Lupin will also acquire Gavis manufacturing facility, which will support its inhalation R&D centre in Coral Springs of Florida.

Gavis founder and CEO Dr Veerappan Subramanian said: "This is a time of globalisation for the specialty pharmaceutical industry and Gavis is well-positioned to capitalise on this exciting opportunity."

Lupin develops and markets different branded and generic formulations, as well as biotechnology products and active pharmaceutical ingredients (APIs).

Its products are used in applications, including cardiovascular, diabetology, asthma, paediatric, central nervous system (CNS), and anti-infective.